These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Breast cancer risk with postmenopausal hormonal treatment. Collins JA; Blake JM; Crosignani PG Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813 [TBL] [Abstract][Full Text] [Related]
4. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483 [TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy and estrogen-dependent cancers. Birkhäuser M Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():99-114. PubMed ID: 7874193 [TBL] [Abstract][Full Text] [Related]
6. Clinical use of progestins in the menopausal patient: dosage and duration. Gambrell RD J Reprod Med; 1982 Aug; 27(8 Suppl):531-8. PubMed ID: 7131446 [TBL] [Abstract][Full Text] [Related]
7. The endometrium--from estrogens alone to TSECs. Pickar JH Climacteric; 2009 Dec; 12(6):463-77. PubMed ID: 19905899 [TBL] [Abstract][Full Text] [Related]
8. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL; Chao HT; Cheng MH; Wang PH Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794 [TBL] [Abstract][Full Text] [Related]
9. [Effects of raloxifene on other organs without bone: uterus]. Nozaki M Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132 [TBL] [Abstract][Full Text] [Related]
11. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland. Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244 [TBL] [Abstract][Full Text] [Related]
12. Progestin replacement in the menopause: effects on the endometrium and serum lipids. Williams DB; Moley KH Curr Opin Obstet Gynecol; 1994 Jun; 6(3):284-92. PubMed ID: 8038417 [TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy and ovarian cancer risk--any news? Riman T Acta Obstet Gynecol Scand; 2007; 86(9):1032-4. PubMed ID: 17712640 [No Abstract] [Full Text] [Related]
14. Menopausal hormones and risk of ovarian cancer. Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062 [TBL] [Abstract][Full Text] [Related]
16. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women. Bjarnason NH Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050 [No Abstract] [Full Text] [Related]
17. Cancer issues. Marsden J; Sturdee D Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643 [TBL] [Abstract][Full Text] [Related]
18. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women]. Lyytinen H; Ylikorkala O Duodecim; 2011; 127(3):235-42. PubMed ID: 21438346 [TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. van de Weijer PH; Mattsson LA; Ylikorkala O Maturitas; 2007 Mar; 56(3):231-48. PubMed ID: 17034966 [TBL] [Abstract][Full Text] [Related]
20. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought. Speroff L Menopause; 2008; 15(2):393-400. PubMed ID: 17925662 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]